Navigation Links
CV Therapeutics Receives European Marketing Authorization for Ranolazine for the Treatment of Patients With Chronic Angina
Date:7/10/2008

PALO ALTO, Calif., July 10 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. (Nasdaq: CVTX) announced today that it has received marketing authorization from the European Medicines Agency (EMEA) for ranolazine for the treatment of patients with chronic angina in all 27 European Union (EU) member states. This approval follows a positive opinion from the EMEA Committee for Medicinal Products for Human Use (CHMP) on April 24, 2008.

Ranolazine is approved for use in Europe as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line antianginal therapies. Ranolazine is approved for use in 375 mg, 500 mg and 750 mg doses, administered twice daily.

The approved European labeling reflects data from the MERLIN TIMI-36 and other recently reported studies, including data showing statistically significant reductions in ventricular arrhythmias with ranolazine. The labeling also notes that the ability of ranolazine to reduce cellular calcium overload is expected to improve myocardial relaxation and decrease left ventricular diastolic stiffness.

"We expect ranolazine could be available to patients and physicians across Europe beginning in the first part of 2009, as we continue to see very strong interest from potential commercial partners," said Louis G. Lange, M.D., Ph.D., chairman and chief executive officer of CV Therapeutics. "Revenues from European sales of ranolazine would represent a fourth product-related revenue stream for CV Therapeutics."

There are currently 48-50 million angina prescriptions written annually in the largest five EU member countries (UK, Germany, France, Spain and Italy).

"Considering the well-established ne
'/>"/>

SOURCE CV Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Lorus Therapeutics Provides an Update on Progress in Virulizin(R) Development Program
2. Arete Therapeutics Names James Sabry, M.D., Ph.D., President and Chief Executive Officer
3. Nabriva Therapeutics Announces Appointment of New CEO
4. Pearl Therapeutics Closes $18 Million Financing Round Led By Committed Investors
5. Lorus Therapeutics Announces Publication of a Clinical Study Demonstrating Encouraging Results with LOR-2040 in Combination with Cytarabine in Patients with Acute Myeloid Leukemia (AML)
6. Joseph B. Bolen, Ph.D. from Millennium to Conference Chair Cancer Sessions at IBCs Drug Discovery & Development of Innovative Therapeutics Conference
7. Tobira Therapeutics Inc. Announces Senior Management Team
8. Duska Therapeutics Obtains Standard & Poors Listing
9. Spectral announces continuing support for the combination of EAA(TM) and anti-endotoxin therapeutics
10. FDA Approves Quark IND for DGFi, an siRNA Therapeutic Based on Silence Therapeutics Unique Proprietary Chemistry
11. Sirion Therapeutics Announces FDA Approval of Durezol(TM) for Treatment of Postoperative Ocular Inflammation and Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... , October 24, 2014 ... Markets ( http://www.researchandmarkets.com/research/t5t5pd/the_global_market ) has announced the addition ... Nanotubes, Graphene And Other 2-D Nanomaterials " ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,CNTs and graphene are ... known to man, with a performance-per-weight greater ...
(Date:10/22/2014)... 21, 2014 The North American crystal ... North America with analysis and forecast of revenue. This ... is expected to reach $623.6 million by 2018, at ... Browse through the TOC of the North American crystal ... in-depth analysis provided. This also provides a glimpse of ...
(Date:10/22/2014)... Khaimah, UAE (PRWEB) October 22, 2014 ... life science and healthcare projects, announces the addition of ... DRCOG DCH to its advisory team. Dr. Siddiqui will ... team. , A graduate of University College ... was subsequently degreed in medicine in 2001. With further ...
(Date:10/22/2014)... 22, 2014 Nuvilex, Inc. (OTCQB: NVLX) – ... people worldwide are living with diabetes, with  that number ... The global market for diabetes treatments is approximately $500 ... worldwide died from pancreatic cancer.  Pancreatic cancer is the ... in the United States , and ...
Breaking Biology Technology:The Global Market for Carbon Nanotubes, Graphene and Other 2-D Nanomaterials 2The Global Market for Carbon Nanotubes, Graphene and Other 2-D Nanomaterials 3The Global Market for Carbon Nanotubes, Graphene and Other 2-D Nanomaterials 4The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 2The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 3The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 4Dr. Yousef Siddiqui joins the Grace Century Advisory Team 2Nuvilex Brief Analyst Report: Thinking Outside the Box by BrokerBank Securities, Inc. 2
... 14 /PRNewswire-FirstCall/ - Aeterna Zentaris Inc. (NASDAQ: ... development company specialized in oncology and endocrine therapy, ... ("Keryx") (Nasdaq: KERX), has been granted orphan-drug designation ... for perifosine, Aeterna Zentaris, novel, potentially first-in-class, oral ...
... , , , ... Residents and Students now Able to Prepare, Review and Test,Knowledge of Common Medical Procedures ... Elsevier, the ... physicians,residents and students will be able to visualize and review over 300 top,medical procedures ...
... studies have uncovered a number of DNA variants associated ... variants lie outside of genes, posing a challenge to ... In a report published online today in Genome ... functional DNA element associated with prostate cancer, lending new ...
Cached Biology Technology:Aeterna Zentaris Announces Perifosine Has Received Orphan-Drug Designation for the Treatment of Neuroblastoma 2Aeterna Zentaris Announces Perifosine Has Received Orphan-Drug Designation for the Treatment of Neuroblastoma 3Aeterna Zentaris Announces Perifosine Has Received Orphan-Drug Designation for the Treatment of Neuroblastoma 4New Procedures Consult Mobile From Elsevier Enables Clinicians to View Top Medical Procedures From Mobile Devices 2New Procedures Consult Mobile From Elsevier Enables Clinicians to View Top Medical Procedures From Mobile Devices 3New Procedures Consult Mobile From Elsevier Enables Clinicians to View Top Medical Procedures From Mobile Devices 4Prostate cancer risk variant found to be in a functional DNA sequence linked with disease 2Prostate cancer risk variant found to be in a functional DNA sequence linked with disease 3
(Date:10/17/2014)... Copenhagen have shown for the first time how bacteria ... patients, giving them the opportunity to get tremendous insights ... The study also discovered the bacterial growth in chronic ... or slowed down by the immune cells. The researchers ... helped "suffocate" the bacteria, forcing the bacteria to switch ...
(Date:10/16/2014)... conventional thinking on how the bowel lining develops and, ... bowel cancer starts. , The researchers produced evidence that ... ,crypts, that are a feature of the bowel lining, ... cancer development, a controversial finding as scientists are still ... imaging technologies, Dr Chin Wee Tan and Professor Tony ...
(Date:10/15/2014)... N.Y. , Oct. 15, 2014 ... solutions for home and community-based care, today announced ... of implementing Sandata,s Santrax® Electronic Visit Verification™ Solution ... Services is a home health company founded in ... Texas . The study ...
Breaking Biology News(10 mins):Scientists opens black box on bacterial growth in cystic fibrosis lung infection 2Cryptic clues drive new theory of bowel cancer development 2Sandata Announces Case Study with Quality Care Services, Inc. 2
... DALLAS Jan. 30, 2014 Patients who have ... and pay closer attention to their nutritional intake, a ... published in the Journal of Investigative Medicine , ... that despite nutritional counseling over a three-month period, most ...
... expect that plants are food sources, but only after an adult ... new research published in Psychological Science , a journal of ... watching an adult put part of a plant and part of ... of age preferentially identify the plant as the food source. ...
... A Kansas State University engineer has made a breakthrough ... of mechanical and nuclear engineering, and his student researchers ... -- made of interleaved molybdenum disulfide and graphene nanosheets ... store sodium atoms and a flexible current collector. The ...
Cached Biology News:Gastric banding patients should closely monitor nutrition following surgery 2Gastric banding patients should closely monitor nutrition following surgery 3Infants know plants provide food, but need to see they're safe to eat 2Engineer brings new twist to sodium-ion battery technology 2
normal human fibroblasts Source: Cell Lysate Form: Ready to Use Application: Western Blotting Control...
3T3 cells (RSV-transformed) Source: Cell Lysate Form: Ready to Use Application: Western Blotting Control...
PC12 (rat phaeochromocytoma) cells Source: Cell Lysate Form: Ready to Use Application: Western Blotting Control...
Peptide-affinity Purified Polyclonal Antibody to Olfactory Receptor, Family 2, Subfamily H, Member 3...
Biology Products: